At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 154 enrolled
Drug / intervention
Dulaglutide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind Study With an Open-Label Extension Comparing the Effect of Once-Weekly Dulaglutide With Placebo in Pediatric Patients With Type 2 Diabetes Mellitus (AWARD-PEDS: Assessment of Weekly AdministRation of LY2189265 in Diabetes-PEDiatric Study)
In Brief
A Phase 3 clinical trial evaluating Dulaglutide and Placebo for Type 2 Diabetes. Completed, enrolled 154 participants across 61 sites in 11 countries.
Detailed Summary
The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of the study drug dulaglutide compared to placebo in pediatric participants with type 2 diabetes. The study duration is approximately 60 weeks.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes
CountriesBrazil, France, Germany, Hungary, India, Mexico, Puerto Rico, Saudi Arabia, Turkey (Türkiye), United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedNov 2016
Enrollment StartDec 2016
Primary CompletionJun 2021
Study CompletionJan 2022
TodayJul 2026
First PostedNov 15, 2016
Enrollment StartDec 29, 2016
Primary CompletionJun 12, 2021
Study CompletionJan 12, 2022
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 9.6 years ago
Interventions
Dulaglutidedrug
Administered SC
Placebodrug
Administered SC